~~<i id='830897CE66'><strike id='830897CE66'><tt id='830897CE66'><pre id='830897CE66'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

Wikipedia

author：knowledge 2025-09-30 23:06:29 - browse：85

A box of Sudafed PE sinus pressure and pain medicine. -- health coverage from stat — PATRICK T. FALLON/AFP via Getty Images

You would have been forgiven for being surprised on Sept. 12 when a panel of advisers to the Food and Drug Administration concluded that the active ingredient in Sudafed PE and other over-the-counter decongestants is completely ineffective. It was front-page news, birthed myriad explainer stories on the internet, and even inspired a lawsuit against companies that sold the medicine, phenylephrine.

Yet when T.J. Parker, the entrepreneur and pharmacist who sold PillPack to Amazon, saw the news, he tweeted, “Didn’t everyone know this?”

He had a point.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： The FDA must approve intranasal treatments for anaphylaxis

hotspot

explore

knowledge

entertainment

focus

hotspot

ApharmacistholdsaboxofWegovyatapharmacyinProvo,Utah.BloombergphotobyGeorgeFreyFewmedicationshavecapt

WSS

The FDA must approve intranasal treatments for anaphylaxis

New weight loss drugs work. But how can they best be used?

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

3 medical device trends to watch in 2024

Bill would allow buprenorphine prescription for addiction via telehealth

Travis Kelce and the trap of celebrity vaccine endorsements

entertainment

Wikipedia

hotspot

Apple is now the first public company to be valued at $3 trillion

The biotech scorecard for Q1: 17 stock

Bright Health sells Medicare Advantage business to Molina

Chronically ill young patients struggle to find fertility info

Dobbs anniversary: the lost opportunity of abortion as health care

Brain injuries and the importance of a second opinion

Alkermes shareholders re

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

State Dept. review finds Biden bears some blame for Afghanistan failures

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

explore

3 medical device trends to watch in 2024

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Burning questions for the 2024 JPM Healthcare Conference

U.K. sequencing study surfaces new findings about tumor DNA

J&J to buy cancer drug developer Ambrx Biopharma

Key Senate panel to consider PBM, drug pricing reform package

knowledge

entertainment

focus

hotspot